Clinical Trials
MB-CART20.1 Phase I Trial in Advanced Melanoma Terminated Due to Severe Toxicities
Balke-Want et alEuropean Journal of Cancer

The prospective, open-label phase I MB-CART20.1 trial evaluated the safety, tolerability, kinetics, and preliminary antitumor activity of autologous CD20-directed CAR T cells in patients with advanced melanoma refractory to standard approved treatments. Rationale was based on prior identification of CD20-expressing cells within the melanoma microenvironment, including tumor-associated B cells and putative cancer stem cells. Following lymphodepleting chemotherapy, seven patients received a single CAR T-cell infusion using a 3+3 dose-escalation scheme: three received dose level 1 (1.0 × 10⁵ cells/kg) and four received dose level 2 (1.0 × 10⁶ cells/kg). All participants had received immune checkpoint inhibitors within 6 months prior to leukapheresis and exhibited reduced expression of exhaustion markers on CD8+ T cells.
Safety evaluations revealed severe dose-limiting toxicities at dose level 2, consisting of grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) and grade 4 hepatotoxicity; no dose-limiting toxicities occurred at dose level 1. Across all seven patients, 43 serious treatment-emergent adverse events were documented. Efficacy was transient, with three patients achieving stable disease at week 16 and all patients experiencing disease progression by month 6. Although MB-CART20.1 achieved robust in vivo expansion, the severe dose-limiting toxicities at dose level 2 and lack of durable clinical benefit led to early trial termination. Correlative analyses indicated that CD19+ CD24+ CD27+ regulatory B-cell frequency trended to associate with disease progression and inversely correlate with toxicity, suggesting that regulatory B-cell depletion and patient treatment history may contribute to distinct CAR T-associated immunotoxicities in melanoma.
Key Takeaways
- Dose-limiting toxicities occurred in two of four patients treated at dose level 2 (grade 3 ICANS and grade 4 hepatotoxicity), contributing to 43 serious treatment-emergent adverse events across seven patients and prompt trial termination.
- Antitumor activity was limited and non-durable, with stable disease recorded in three patients at week 16 followed by disease progression in all treated individuals by month 6 despite robust in vivo CAR T-cell expansion.
- Circulating CD19+ CD24+ CD27+ regulatory B-cell frequencies trended to associate with progressive disease and inversely correlate with observed immunotoxicity.
Read the original sourceEuropean Journal of Cancer
